Section Arrow
IFRX.NASDAQ
- InflaRx NV
Quotes are at least 15-min delayed:2026/05/12 11:52 EDT
Regular Hours
Last
 2.375
-0.125 (-5.00%)
Day High 
2.51 
Prev. Close
2.5 
1-M High
2.9489 
Volume 
1.21M 
Bid
2.37
Ask
2.38
Day Low
2.31 
Open
2.45 
1-M Low
0.9701 
Market Cap 
180.73M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 2.22 
20-SMA 1.85 
50-SMA 1.3 
52-W High 2.9489 
52-W Low 0.7113 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.63/-0.52
Enterprise Value
181.37M
Balance Sheet
Book Value Per Share
0.60
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
29.33K
Operating Revenue Per Share
0.00
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ERNAErnexa Therapeutics Inc.13.75+6.54+90.71%-- 
GERNGeron Corp1.4153+0.0253+1.82%-- 
ABCLAbCellera Biologics4.815-0.435-8.29%-- 
RXRXRecursion Pharmaceuticals3.085-0.175-5.37%-- 
TNYATenaya Therapeutics1.0151+0.017+1.70%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.